Нежелательные лекарственные реакции со стороны ЖКТ и антибиотикоассоциированная диарея при применении антибиотиков в амбулаторной практике: профилактика и лечение

С.М.  Захаренко; Ирина Вениаминовна Андреева; Ольга Ульяновна Стецюк

doi:10.36488/cmac.2019.3.196-206

Нежелательные лекарственные реакции со стороны ЖКТ и антибиотикоассоциированная диарея при применении антибиотиков в амбулаторной практике: профилактика и лечение

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(3):196-206

Захаренко С.М., Андреева И.В., Стецюк О.У.

10.36488/cmac.2019.3.196-206

антибиотики безопасность нежелательные лекарственные реакции диарея антибиотикоассоциированная диарея эрадикация H pylori пробиотики Lactobacillus spp S boulardii

Раздел

Болезни и возбудители

Тип

Обзор

Публикация

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(3):196-206

Аннотация Авторы Литература PDF Статистика Репринты

Аннотация

Нежелательные лекарственные реакции со стороны желудочно-кишечного тракта, нередко с развитием антибиотикоассоциированной диареи, являются самыми частыми неблагоприятными эффектами антибактериальной терапии в амбулаторной практике. В обзоре приведены современные подходы к профилактике и лечению данных состояний; особое внимание уделено возможности повышения эффективности и безопасности схем эрадикации Helicobacter pylori.

Захаренко С.М.

ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия

Андреева Ирина Вениаминовна

Irina.Andreeva@antibiotic.ru

0000-0001-7916-1488

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

Стецюк Ольга Ульяновна

0000-0002-7316-9187

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

1. Makins R., Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2(4):421-429. DOI: 10.1517/14740338.2.4.421
2. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf. 2000;22(3):237-249. DOI: 10.2165/00002018-200022030-00007
3. Nassar N.N., Gregg C.R. Esophageal Infections. Curr Treat Options Gastroenterol. 1998;1(1):56-63. DOI: 10.1007/s11938-998-0009-7
4. Mahon B.E., Rosenman M.B., Kleiman M.B. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139(3):380-384. DOI: 10.1067/mpd.2001.117577
5. Kanner E.V., Gorelov A.V., Krutikhina S.B. Antibiotic-associated diarrhea in children: a modern view of the problem. Medicinskij sovet. 2017;1:226-230. Russian. (Каннер Е.В., Горелов А.В., Крутихина С.Б. Антибиотик-ассоцииированная диарея у детей: современный взгляд на проблему. Медицинский совет. 2017;1:226-230.)
6. Giannelli F.R. Antibiotic-associated diarrhea. JAAPA. 2017;30(10):46-47. DOI: 10.1097/01.JAA.0000524721.01579.c9
7. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292-307. DOI: 10.1159/000016879
8. Owens R.C. Jr., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl. 2):S144-S157. DOI: 10.1086/428055
9. Salvo F., De Sarro A., Caputi A.P., Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf. 2009;8(1):111-118. DOI: 10.1517/14740330802527984
10. Högenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27(4):702-710. DOI: 10.1086/514958
11. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573-581. DOI: 10.1093/clind/15.4.573
12. Osadchuk M.A., Svistunov A.A. Antibiotic-associated diarrhea in clinical practice.Voprosy sovremennoj pediatrii. 2014;13(1):102-108. Russian. (Осадчук М.А., Свистунов А.А. Антибиотикоассоциированная диарея в клинической практике. Вопросы современной педиатрии. 2014;13(1):102-108.)
13. Mitchell D.K., Van R., Mason E.H., Norris D.M., Pickering L.K. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Pediatr Infect Dis J. 1996;15(6):514-519. DOI: 10.1097/00006454-199606000-00008
14. Vanderhoof J.A., Whitney D.B., Antonson D.L., Hanner T.L., Lupo J.V., Young R.J. Lactobacillus GG in the prevention of antibioticassociated diarrhea in children. J Pediatr. 1999;135(5):564-568. DOI: 10.1016/s0022-3476(99)70053-3
15. Arvola T., Laiho K., Torkkeli S., Mykkänen H., Salminen S., Maunula L., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104(5):e64. DOI: 10.1542/peds.104.5.e64
16. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22-26. DOI: 10.1097/00005176-200307000-00004
17. La Rosa M., Bottaro G., Gulino N., Gambuzza F., Di Forti F., Inì G., et al. [Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study]. Minerva Pediatr. 2003;55(5):447-452. PMID: 14608267
18. Seki H., Shiohara M., Matsumura T., Miyagawa N., Tanaka M., Komiyama A., et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003;45(1):86-90. DOI: 10.1046/j.1442-200x.2003.01671.x
19. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590. DOI: 10.1111/j.1365-2036.2005.02356.x
20. Damrongmanee A., Ukarapol N. Incidence of antibioticassociated diarrhea in a pediatric ambulatory care setting. J Med Assoc Thai. 2007;90(3):513-517. PMID: 17427529
21. Ruszczyński M., Radzikowski A., Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-561. DOI: 10.1111/j.1365-2036.2008.03714.x
22. Bargozzi E., Gaiazzi M., Meneghin F., Ramponi G., Zuccotti G., Cardile S., et al. Antibiotic associated diarrhea in children: What happens in real life? Digestive and Liver Disease. 2013;45:e263-e311. DOI: 10.1016/j.dld.2013.08.150
23. Wiström J., Norrby S.R., Myhre E.B., Eriksson S., Granström G., Lagergren L., et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001;47(1):43-50. DOI: 10.1093/jac/47.1.43
24. Peeters T.L., Matthys G., Depootere I., Cachet T., Hoogmartens J., Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol. 1989;257:470-474. DOI: 10.1152/ajpgi.1989.257.3.G470
25. Caron F., Bouaniche M., Delatour F., Ducrotte P., Torlotin J.C., Denis P., et al. B. Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob Agents Chemother. 1996;40:1796-800. PMID: 8843283
26. Shevyakov M.A. Antibiotic-associated diarrhea and intestinal candidiasis: treatment and prevention options. Antibiotiki i himioterapija. 2004;49(10):26-29. Russian. (Шевяков М.А. Антибиотик-ассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики. Антибиотики и химиотерапия. 2004;49(10):26-29.)
27. Jernberg C., Lofmark S., Edlund C., Jansson J.K. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1:56-66. DOI: 10.1038/ismej.2007.3
28. Sjölund M., Tano E., Blaser M.J., Andersson D.I., Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerg Infect Dis. 2005;11:1389-1393. DOI: 10.3201/eid1109.050124
29. Jakobsson H., Wreiber K., Fall K., Fjelstad B., Nyrén O., Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39:757-763. DOI: 10.1080/00365540701299608
30. Löfmark S., Jernberg C., Jansson J.K., Edlund C. Clindamycininduced enrichment and longterm persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006,58:1160-1167. DOI: 10.1093/jac/dkl420
31. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing. PLoS Biol. 2008;6(11):e280. DOI: 10.1371/journal.pbio.0060280
32. Zaura E., Brandt B.W., Teixeira de Mattos M.J., Buijs M.J., Caspers M.P., Rashid M.U., et al. Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces. MBio. 2015;6(6):e01693-15. DOI: 10.1128/mBio.01693-15
33. Palleja A., Mikkelsen K.H., Forslund S.K., Kashani A., Allin K.H., Nielsen T., et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-1265. DOI: 10.1038/s41564-018-0257-9
34. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67:302-307. PMID: 9864230
35. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324(7350):1361. DOI: 10.1136/bmj.324.7350.1361
36. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16(8):1461-1467. DOI: 10.1046/j.1365-2036.2002.01318.x
37. Johnston B.C., Supina A.L., Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ. 2006;175(4):377-383. DOI: 10.1503/cmaj.051603
38. Szajewska H., Ruszczyński M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-372. DOI: 10.1016/j.jpeds.2006.04.053
39. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. DOI: 10.1002/14651858.CD004827.pub3
40. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and metaanalysis. JAMA. 2012;307(18):1959-1969. DOI: 10.1001/jama.2012.3507
41. Goldenberg J.Z., Ma S.S., Saxton J.D., Lo C.K., Beardsley J., Mertz D., et al. Probiotics for the prevention of Clostridium difficileassociated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095. DOI: 10.1002/14651858.CD006095.pub3
42. McFarland L.V. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. Benef Microbes. 2015;6(2):189-194. DOI: 10.3920/BM2014.0034
43. Goldenberg J.Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;12:CD004827. DOI: 10.1002/14651858.CD004827.pub4
44. Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibioticassociated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157. DOI: 10.1111/apt.13404
45. Jafarnejad S., Shab-Bidar S., Speakman J.R., Parastui K., Daneshi-Maskooni M., Djafarian K. Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) but Not the Elderly (>65 Years): A Meta-Analysis. Nutr Clin Pract. 2016;31(4):502-513. DOI: 10.1177/0884533616639399
46. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., et al. Probiotics for the prevention of Clostridium difficileassociated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12: CD006095. DOI: 10.1002/14651858.CD006095.pub4
47. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With MetaRegression Analysis. Gastroenterology. 2017;152(8):1889-1900. DOI: 10.1053/j.gastro.2017.02.003
48. Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients – A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4). pii: E21. DOI: 10.3390/antibiotics6040021
49. Guo Q., Goldenberg J.Z., Humphrey C., El Dib R., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827. DOI: 10.1002/14651858.CD004827.pub5
50. WGO Practice Guideline. Probiotics and Prebiotics. World Gastroenterology Organization. 2012. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. Accessed 20.10.2019.
51. Szajewska H., Canani R.B., Guarino A., Hojsak I., Indrio F., Kolacek S., et al; ESPGHAN Working Group for Probiotics and Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. DOI: 10.1097/MPG.0000000000001081
52. Guarner F., Sanders M.E., Eliakim R., Fedorak R., Gangl A., Garish J., et al.; World Gastroenterology Organization Global Guidelines. Probiotics and prebiotics. February 2017. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english. Accessed 20.10.2019.
53. Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI: 10.1136/gutjnl-2016-312288
54. Wermeille J., Cunningham M., Dederding J.P., Girard L., Baumann R., Zelger G., et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219. PMID: 11981460
55. Sanches B., Coelho L., Moretzsohn L., Vieira G. Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13(6):572-576. DOI: 10.1111/j.1523-5378.2008.00649.x
56. Gong Y., Li Y., Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a metaanalysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530-6543. PMID: 26131283
57. Bulgakov S.A. Side effects of antihelicobacter therapy. Al'manah klinicheskoj mediciny. 2006;14:20-23. Russian. (Булгаков С.А. Побочные эффекты при антихеликобактерной терапии. Альманах клинической медицины. 2006;14:20-23.)
58. Marteau P., Rambaud J.C. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev. 1993;12:207-220. DOI: 10.1111/j.1574-6976.1993.tb00019.x
59. Armuzzi A., Cremonini F., Ojetti V., Bartolozzi F., Canducci F., Candelli M., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion. 2001;63(1):1-7. DOI: 10.1159/000051865
60. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-168. DOI: 10.1111/j.1365-2036.2006.03179.x
61. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(5):97-107. DOI: 10.1111/j.1523-5378.2009.00716.x
62. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacteriumcontaining probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. DOI: 10.1097/MCG.0b013e318266f6cf
63. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453. DOI: 10.4321/s1130-01082013000800002
64. Li S., Huang X.L., Sui J.Z., Chen S.Y., Xie Y.T., Deng Y., et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173(2):153-161. DOI: 10.1007/s00431-013-2220-3
65. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-4347. DOI: 10.3748/wjg.v21.i14.4345
66. Lü M., Yu S., Deng J., Yan Q., Yang C., Xia G., et al. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0163743. DOI: 10.1371/journal.pone.0163743
67. Si X.B., Lan Y., Qiao L. A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori. Zhonghua Nei Ke Za Zhi. 2017;56(10):752-759. DOI: 10.3760/cma.j.issn.0578-1426.2017.10.009
68. Fang H.R., Zhang G.Q., Cheng J.Y., Li Z.Y. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7-16. DOI: 10.1007/s00431-018-3282-z
69. Lv Z., Wang B., Zhou X., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A metaanalysis. Exp Ther Med. 2015;9(3):707-716. DOI: 10.3892/etm.2015.2174
70. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180
71. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al.; European Helicobacter Study Group Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report. Gut. 2012;61(5):646-664. DOI: 10.1136/gutjnl-2012-302084

Просмотров

0 Аннотация

0 PDF

0 Цитирования

Аннотация

Просмотров

Поделились

Процитировали Crossref